Constructing the Framework for Disease Modification in Pulmonary Arterial Hypertension

Am J Respir Crit Care Med. 2024 May 15;209(10):1189-1195. doi: 10.1164/rccm.202401-0089PP.

Roham T Zamanian^{1

2}, Jason Weatherald³, Andrew J Sweatt^{1

2}, Anna Hemnes⁴, Moira Rashid⁵, Mitchell A Psotka^{6

7}, Harm J Bogaard⁸, Vinicio de Jesus Perez^{1

2}

¹ Division of Pulmonary, Allergy and Critical Care Medicine and.
² Vera Moulton Wall Center for Pulmonary Vascular Disease, Stanford University, Stanford, California.
³ Department of Medicine, Division of Pulmonary Medicine, University of Alberta, Edmonton, Alberta, Canada.
⁴ Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
⁵ Planned Parenthood of Orange and San Bernandino Counties, California.
⁶ U.S. Food and Drug Administration, Silver Spring, Maryland.
⁷ Inova Schar Heart and Vascular, Falls Church, Virginia; and.
⁸ Department of Pulmonary Medicine, Amsterdam University Medical Center, Amsterdam, The Netherlands.

No abstract available

MeSH terms